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Erythropoiesis’ Stimulating Factors (ESAs) are among the top ten therapeutic
groups with the highest pharmaceutical expenditure in Greece. OBJECTIVES: To
explore the penetration of ESAs in the Greek pharmaceutical market and differ-
ences in pricing levels between originals and biosimilars. METHODS: Data derived
from the IKA-ETAM Social Security Fund, covering almost 50% of insured popula-
tion. Consumption of ESAs (epoetin alfa, darbepoetin alfa, epoetin beta, methoxy
polyethylene glycol epoetin beta, epoetin zeta) was collected from the Central &
Peripheral Pharmacy, dispensing high value medicines for serious diseases on out-
patient basis covering almost 70% geographical area of Greece. Consumption of
epoetins was recorded from 2008 to 2010, classified per strength (IU/mcg), sepa-
rated in originals and biosimilars. The average price per 1000IU of each category
was also estimated for the respective years based on NHS hospital prices.RESULTS:
ESAs consumption in 2008 and 2009 was approximately the same (26 & 27% respec-
tively) while decreasing by 4% reaching 23% in 2010. A 13,8% decrease was also
observed in IKA-ETAM total pharmaceutical expenditure in 2010. ESAs expenditure
in 2008, was €41,4 million corresponding to 99% market share (MSH) of originals
epoetins, leaving only 1% MSH in biosimilar epoetin zeta launched in that year. In
2009 ESAs expenditure reached €43 million, with 94% and 6% MSH for original and
biosimilar ESAs respectively. In 2010 ESAs expenditure was almost halved (€22mil-
lion), due to price cuts and stricter control of prescriptions. Specifically, the MSH of
originals reached 81% and biosimilars 19% respectively. In the reported years prices
of biosimilars were slightly different from that of originals, however as of 2011
higher price differences are observed, favoring the use of biosimilars.
CONCLUSIONS: Biosimilars penetration in Greece is similar with EU, 6% and 6,64%
in 2009 respectively, presenting an increasing rate in 2010. Under the economic
recession Greece is experiencing, biosimilars seem to be a cost saving option.
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OBJECTIVES: On-demand treatment for haemophilia patients with inhibitors is
burdensome to patients and practitioners. Newer bypassing agents with shortened
bleed resolution time resulting in fewer infusions, may impact costs and patient
quality of life (QoL). The study objective was to model the lifetime costs and health-
related QoL outcomes associated with bypassing agents, recombinant activated
Factor VIIa and plasma-derived activated prothrombin complex concentrate (rF-
VIIa, pd-aPCC) in Germany, and investigate the impact of faster bleeding resolution
of a new rFVIIa analogue. METHODS: Assuming a German payer perspective, this
literature-based model tracks a hypothetical cohort of severe haemophilia patients
with inhibitors over their lifetime. A semi-Markov model was used to simulate
patient movement through health states at 3-month intervals. Modeled outcomes
include lifetime direct treatment costs, cost per bleeding episode, life-years, and
quality-adjusted life years (QALYs) across a continuum of home and inpatient care.
One-way sensitivity analyses were performed on all model variables and two-way
sensitivity analyses on key variables. RESULTS:Using base-case assumptions from
the literature, rFVIIa was associated with measurable lifetime cost savings com-
pared with pd-aPCC (€ 2,962,833 vs. € 4,664,971, respectively) and reduced total cost
per bleed compared with pd-aPCC (€ 17,614 vs. € 19,435, respectively). Reducing the
number of rFVIIa infusions per bleed from 2.3 to 1.5 resulted in incremental cost
savings of € 248,033, while 20% utility improvement in rFVIIa conferred a 3.14
additional QALY gain. Sensitivity analyses confirmed the robustness of base case
findings.CONCLUSIONS:This exploratory model is a valuable tool for physicians to
assess the impact of current treatment patterns over a patient’s lifetime and to
potentially identify optimal practice patterns. Availability of bypassing agents with
improved efficacy profiles could result in significant improvement of patient care.
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OBJECTIVES: Evaluate rate of flares in adult SLE patients with active antinuclear
autoantibody positive SLE disease and estimate the incremental direct costs of
flare management. METHODS: A multi-centre retrospective chart review study
extracting patient characteristics, disease activity and severity, and medical re-
source utilization in 5 European countries (France, Germany, UK, Italy and Spain).
Patients were stratified by disease severity at inclusion visit (50% severe) and fol-
lowed-up for 2 years. Severe disease defined as having at least one major domain
actively involved (renal, neurological, cardiovascular or respiratory) and requiring
7.5 mg/day of corticosteroids and/or immunosuppressants. A modification of
SELENA-SLEDAI Flare Index collected retrospectively was used for identifying mild/
moderate and severe flares. Unadjusted mean costs associated with management
of flares were assessed. Health care perspective and country specific data was used
for resources and costs analysis. RESULTS: The total sample included 427 SLE
patients (212 severe, 215 non-severe), mean age: 43.4 years, female: 90.5%. Total
mean number of flares over the study period was 2.29 compared to 1.83 (p0.001)
for severe and non-severe patients respectively. Mean number of mild/moderate
flares was 0.87 compared to 1.32 (p0.001), while mean number of severe flares was
1.42 compared to 0.52 (p0.001) for severe and non-severe patients, respectively.
The mean two year costs for patients experiencing at least one flare over study
period was €9607 compared to €3910 (p0.001) without flares. Exploratory flare
analysis showed a mean 2 year increase in costs of €4525 (p0.01) per severe flare
(no statistical significance for mild/moderate flares). CONCLUSIONS: Severe pa-
tients experience both a higher number of flares and more severe flares compared
to non-severe patients. Patients experiencing at least one flare over the study pe-
riod are 2.5 times more costly than patients without flares; the presence of severe
flares in SLE patients has a significant impact on the healthcare system.
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OBJECTIVES:The rational use of resources is essential for granting sustainability at
any healthcare system. This study aims to evaluate the best anti-inflamatory med-
ication regarding costs consumption from private payer’s perspective. METHODS:
400 medical charts from 3 private hospitals in Curitiba city were accessed retro-
spectively from November to April (2010) and selected based on the use of intrave-
nous ketoprophene (200mg/day), ketorolac (60mg/day), parecoxib (40mg/day) or
tenoxicam (40mg/day) at the immediate post-operative adult patients from ortho-
pedic surgeries period and based on the existence of hospital’s billing information.
One hundred twenty-one cases were recruited. Resource use considered were ant-
acid, antiemetic and analgesic drugs, infusion equipment, medication costs (fac-
tory list prices) and labor costs were estimated from the amount of minutes per day
to administering the medications. The minimum monthly wage for a nurse accord-
ing to the Brazilian nurses union was considered (593.75 USD). Costs are expressed
in 2010 USD. RESULTS: Parecoxib presented the least daily resource consuming
profile with an average of 33.52 USD compared to 68.27; 67.16 and 75.05 USD for
ketoprophene, ketorolac and tenoxicam. Daily average expenditure on the con-
sumption of antacid analgesic and antiemetic medications was 6.00, 10.19, 12.43
and 8.50 USD for parecoxib, ketoprophene, ketorolac and tenoxicam (PC/KP/KL/TM)
respectively. Total time expenditure per day and costs were 12.5 min (4.96 USD),
26.75 min (10.59 USD), 27.43min (10.85 USD) and 25.20 min (9.97 USD) for PC/KP/
KL/TM respectively. Daily savings by using parecoxib were found in 2.53, 13.04 and
7.16 USD against KP/KL/TM, respectively. CONCLUSIONS: Parecoxib was found to
be the less costly alternative to the hospital by rationing the number of adminis-
trations per day, the use of antacid, analgesic and antiemetic medications and the
total labor time costs for administering the medications.
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OBJECTIVES: Cost of chemotherapy-induced febrile neutropenia (FN) in the United
States has been reported to be substantial. Little is known about the cost of FN in
other countries or about costs of follow-on care and subsequent FN events.
METHODS: Data were obtained from an observational study of supportive care in
patients with non-Hodgkin’s lymphoma (NHL) receiving CHOP-14 or CHOP-21 che-
motherapy (rituximab) predominantly across Europe. FN was defined as single
oral temperature of38.3°C or temperature of38.0°C for1 hour, and neutrophil
count of 0.5x109/L or 1.0x109/L and predicted to fall below 0.5x109/L. Patients
developing FN in a given cycle (“FN patients”), starting with the first cycle, were
matched (1:1, without replacement) on age, tumor stage, chemotherapy, and other
factors to those not developing FN in that cycle (“comparison patients”), irrespec-
tive of FN experience in subsequent cycles. FN-related healthcare utilization and
costs (estimated from UK National Health Service perspective [2010]) were tallied
for patients from the match cycle through the last chemotherapy cycle
(“follow-up”). RESULTS: Eighteen percent of patients (331/1829) in the observa-
tional study experienced a total of 479 FN events, the majority (77%) of which
required inpatient care. A total of 295 FN patients were matched to comparison
patients for these analyses; baseline characteristics were similar between groups.
During follow-up, FN patients averaged 1.44 (95%CI 1.34-1.56) FN events and com-
parison patients averaged 0.15 (0.10-0.21) FN events, and corresponding mean
number of FN-related hospital days was 6.21 (5.28-7.17) and 0.63 (0.30-1.02). Mean
total cost was £5744 (£4893-£6664) higher for FN patients than comparison patients,
with 71% of the difference attributable to care in the index cycle (£4051 [£3633-
£4485]) and 29% attributable to care in post-index cycles (£1693 [£917-£2447]).
CONCLUSIONS: Cost of chemotherapy-induced FN among NHL patients in Euro-
pean clinical practice is substantial, with a sizable percentage attributable to fol-
low-on care and subsequent FN events.
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OBJECTIVES: To determine the annual direct medical cost of the management of
adult patient with active antinuclear autoantibody positive SLE. METHODS: LUCIE
is a multicenter, observational, retrospective study carried out in five European
countries, including France. SLE patients characteristics, disease severity (severe
patient defined as having at least one major domain actively involved at inclusion:
renal, neurological, cardiovascular or respiratory AND Requiring corticosteroids 
7.5 mg/day and/or immunosuppressants), flares rate, health care consumption
(laboratory tests, biopsies and/or imaging tests, medications, specialist visit, hos-
pitalisations) were collected retrospectively over a two-years period. The French
national health insurance perspective was considered when estimating the aver-
age annual direct cost using official cost database. Major cost drivers associated
with SLE and flares management were identified by multivariate regression
models. RESULTS: Eight French SLE centres participated in the study, and included
96 consecutive patients: mean age 39.911.9 years, 93.5% females. The mean SLE
duration was 9.86.6 years, the mean SELENA-SLEDAI score, a semiquantitative
index of SLE activity was 7.75.1. On average, SLE patients had 1.10.59 flares/year.
The annual unadjusted mean direct medical cost of SLE patients was €4116
(SD5498). In severe patients the cost was 1.3 times higher: €4660 versus €3560 in
non-severe patients (NS). Medical treatment represents the largest component of
the average annual direct cost of SLE patients (61.8%) and was higher in severe
patients (7214€ versus 1855€, p0.030). Biological drugs, even though prescribed to
only 10.8% of patients, represented 3.4% of the annual total medical treatment cost.
The multivariate regression model showed that each severe flare increases cost by
€1230 (p0.2). CONCLUSIONS: The annual direct medical cost of active SLE is sig-
nificant especially for patients experiencing severe flare and is mostly driven by the
cost of medication.
PSY21
PREDICTORS OF DULOXETINE ADHERENCE AND PERSISTENCE IN PATIENTS
WITH FIBROMYALGIA
Cui Z1, Zhao Y1, Fang Y2, Chen Y3, Novick D1, Faries D1
1Eli Lilly and Company, Indianapolis, IN, USA, 2inVentiv Clinical Solutions, Indianapolis, IN,
USA, 3inVentiv Clinical Solutions LLC, Indianapolis, IN, USA
OBJECTIVES: Medication adherence and persistence are important in the treat-
ment of fibromyalgia. The objective of this study is to examine the predictors of
adherence and persistence to duloxetine therapy among commercially-insured
fibromyalgia patients. METHODS: This study analyzed medical and pharmacy re-
cords for commercially-insured patients aged 18-64 with fibromyalgia who initi-
ated (no prior 90-day use) duloxetine in 2008. Patients selected had continuous
health insurance enrollment for 12 months preceding and following duloxetine
initiation, at least 1 fibromyalgia diagnosis during the 12 months before, or 1 month
after, the initiation date, and at least 30-day cumulative duloxetine supply over the
12-month post-index period. Adherence to duloxetine was measured by medica-
tion possession ratio (MPR  post 1-year total duloxetine supply days/365), with
high adherence defined as MPR 0.8. Persistence was defined as the length of
therapy (LOT) from the index date to the earliest of the ending date of the last
prescription, the date of the first gap of more than 15 days between prescriptions,
or the end of study period (12 months). Demographic and clinical predictors of
adherence and persistence were examined via multivariate logistic regression
(MLR) and classification and regression trees (CART). RESULTS: Among 4,660 du-
loxetine patients, 33% achieved high adherence. Factors associated with high ad-
herence from MLR included older age, North Central and Northeast regions, prior
venlafaxine, pregabalin, SSRIs or other antidepressants use, or comoribid dyslipi-
demia, osteoarthritis, or skin and subcutaneous tissue disorders (all p0.05). CART
analysis revealed that patients with prior use of antidepressants, age 46, or prior
osteoarthritis disorder had higher MPR (all p0.05), and patients aged 45 with a
history of SSRI, venlafaxine or anticonvulsant use had longer LOT (all p0.05).
CONCLUSIONS: One-third of fibromyalgia patients on duloxetine achieved high
adherence. Patients with high adherence and persistence to duloxetine were sig-
nificantly older and had prior antidepressant use.
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OBJECTIVES: To compare the costs of adding pregabalin or gabapentin to existing
therapy in patients with peripheral neuropathic pain (PNeP) in routine medical
practice in a Spanish setting. METHODS: A retrospective database analysis was
performed using patients’ medical claims records. Medical records from male and
female patients, with PNeP, 18 years, in whom pregabalin, or gabapentin was
initiated between 2006 and 2008 were included in the analysis. The economic
model included health care resource utilization and corresponding costs, from a
third-payer perspective. Estimates of indirect costs, due to sick leave were
included. RESULTS: A total of 1160 records were eligible for analysis: 764 (65.7%)
treated with pregabalin and 399 (34.3%) gabapentin. Patients in both groups were
comparable. No significant differences were observed for previous average number
of analgesics: pregabalin 2.7 (0.1); gabapentin 2.8 (0.1), p0.362. However, concom-
itant use of analgesics was higher in gabapentin cohort; 3.2 (0.1) versus 2.7 (0.1);
p0.003, mainly due to a higher utilization of NSAIDs (74.9% versus 69.5%; p0.018)
and opioids (27.7% vs. 17.9%; p0.031). Adjusted mean (95% CI) total costs per
patient were significantly lower in pregabalin group; €2514 (2228-2800) versus €3241
(2853-3630); p 0.003, due to minor labour productivity losses; €1067 (790-1345)
versus €1633 (1256-2009); p0.018, and lower adjusted health care costs; €1447
(1380-1513) versus €1609 (1519-1698); p0.004. The higher drug acquisition costs for
pregabalin [€351 versus €191; p0.001) was compensated for by lower overall
health care costs, mainly in medical visits, physiotherapy, hospitalization days and
concomitant analgesics. CONCLUSIONS: In a population setting in Spain, pregaba-
lin treated patients with PNeP were considerable less costly for the healthcare
provider than those treated with gabapentin in routine clinical practice. The higher
acquisition cost of pregabalin was compensated largely by lower costs in the other
components of health care costs. Patients treated with pregabalin had significantly
less sick leaves than gabapentin treated patients.
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OBJECTIVES: Adding pregabalin or gabapentin to existing therapy in patients with
painful radiculopathies in routine medical practice in a Spanish health care setting.
METHODS: A retrospective database analysis was performed using patients’ med-
ical claims records from BSA. Medical records from male and female, with cervical,
dorsal or lumbar painful radiculopathy, 18 years, in whom pregabalin, or gabap-
entin was initiated between 2006 and 2008 were included in the analysis. The
economic analysis included healthcare resource utilization and corresponding
costs from a third-payer perspective. Estimates of indirect costs, due to sick leave
were also included. RESULTS: A total of 571 records were eligible for analysis: 378
(66.2%) treated with pregabalin and 193 (33.8%) gabapentin. Time since diagnosis,
duration of treatment, prevalence of most comorbidities and previous use of anal-
gesics were comparable. However, concomitant use of analgesics was higher in
gabapentin cohort; 3.1 (1.7) versus 2.8 (1.8); p0.05, mainly due to a higher utiliza-
tion of opioids (31.1% vs. 21.2%; p0.05) and non-narcotic (63.7% vs. 52.1%; p0.01)
drugs. Adjusted total costs per patient were significantly lower in pregabalin group;
€2472 (2101-2836) versus. €3346 (2866-3825); p 0.005, due to minor absenteeism
costs; €1012 (658-1365) versus €1595 (1129-2062); p0.042, and lower adjusted
health care costs; €1,460 (1,360-1,560) versus €1750 (1618-1882); p0.001. The higher
drug acquisition costs for pregabalin [€343 vs. €222; p0.001) was largely compen-
sated for by lower overall health care costs, mainly in primary care medical visits,
hospitalization days and concomitant analgesics. CONCLUSIONS: In a population
setting in Spain, pregabalin treated patients with painful radiculopathies were
considerable less costly for the health care provider than those treated with gaba-
pentin in routine clinical practice. The higher acquisition cost of pregabalin was
compensated largely by lower costs in the other components of health care costs.
Patients treated with pregabalin had significantly less sick leaves than gabapentin
treated patients.
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OBJECTIVES: In recent years there has been a large increase in the number of
morbidly obese persons subject to hospital surgery. In Portugal, 14% of the popu-
lation of working age is obese. As in other countries these numbers have been
rising and it is well known that obese individuals have an increased risk of mor-
bidity and premature death from various diseases. We estimate the impact of
obesity on the health sector by calculating the costs of hospital inpatient care
associated with obesity in Portugal. METHODS: A prevalence-based cost of treat-
ment approach is adopted. Hospital episode micro data are drawn from the Na-
tional Health Service’s (NHS) DRG information system for 2008 (n965 212). Besides
episodes where the main diagnosis is obesity, population attributable fractions are
calculated for 16 co-morbidities (CID-9-MC), including diabetes type 2, musculosk-
eletal diseases, cardiovascular conditions and some types of cancer. Relative risks
are drawn from a recent meta-analysis of large-scale prospective studies and prev-
alence data from a nationally representative examination survey that recorded
anthropometric data. Unit cost data are taken from an NHS database. RESULTS:
The hospital inpatient costs of obesity in NHS hospitals in 2008 are estimated as €
85.9 million. This corresponds to 0.92% of annual NHS expenditure. The three
major contributors to this total are osteoarthritis (19.9%), obesity (15.4%) and isch-
emic heart disease (14.7%). If circulatory and cerebrovascular system diagnoses are
grouped together, they become the largest contributors to total costs.
CONCLUSIONS: The structure of costs by diagnosis is different to that commonly
found in ambulatory care. Despite the sharp increase in the number of persons
subject to obesity surgery the overall inpatient care costs have remained largely
stable over time. There has been a large increase in the resources used to treat
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